Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy
© 2015 American Association for Cancer Research. Purpose: Blood-based circulating-free (cf) tumor DNA may be an alternative to tissue-based EGFR mutation testing in NSCLC. This exploratory analysis compares matched tumor and blood samples from the FASTACT-2 study. Experimental Design: Patients were...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
格式: | 雜誌 |
出版: |
2018
|
主題: | |
在線閱讀: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84938399710&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/44286 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
機構: | Chiang Mai University |
成為第一個發表評論!